BSX (bostonscientific.com) יחס שווי שוק לשווי בספרים

The price-to-book ratio history for Boston Scientific (BSX), where the current level is 2.65, confirms clinic loyalty to BSX specific stents. Stable FCF and an aging population guarantee sustainable income. However, the risk of certification delays for new devices and pressure from government pricing programs create certain fundamental challenges for asset valuation.

The high value of Boston Scientific (BSX) intellectual property in minimally invasive cardiology and endoscopy often creates a significant gap between tangible assets and market valuation. By analyzing the history of the market-to-book ratio, an investor can determine the extent of the premium paid for future innovations or identify business undervaluation, isolating short-term market volatility from the fundamental stability of the company's equity.